Minireview: Won't get fooled again: The nonmetabolic roles of peroxisome proliferator-activated receptors (PPARs) in the heart

Molecular Endocrinology

Volumn 24, Issue 6, 2010, Pages 1111-1119

  Lockyer, Pamela ^a   Schisler, Jonathan C ^a   Patterson, Cam ^a   Willis, Monte S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; PROTEIN C JUN; TRANSCRIPTION FACTOR AP 1;

ANGIOGENESIS; CARDITIS; CELL CYCLE REGULATION; CELL PROLIFERATION; DRUG ACTIVITY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEART VENTRICLE HYPERTROPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SHORT SURVEY;

ANIMALS; CARDIOMEGALY; HUMANS; INFLAMMATION; MYOCARDIUM; OXIDATIVE STRESS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA;

EID: 77954821171     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0374     Document Type: Short Survey

References (80)

1. Taegtmeyer H 1994 Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol 19:59-113
2. Neely JR, Rovetto MJ, Oram JF 1972 Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 15:289-329
3. Robinson E, Grieve DJ 2009 Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther 122:246-263
4. Madrazo JA, Kelly DP 2008 The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol 44:968-975
5. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N 2005 Inhibition of NF-κB signaling by fenofibrate, a peroxisome proliferator-activated receptor-α ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 23:323-330
6. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, Kalina Z, Herman ZS 1998 Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyper-lipoproteinemia IIb. Int J Clin Pharmacol Ther 36:345-349
7. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A 1998 Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393:790-793
8. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B 1999 Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 274:32048-32054
9. Delerive P, De Bosscher K, Vanden Berghe W, Fruchart JC, Haegeman G, Staels B 2002 DNA binding-independent induction of IκBαgene transcription by PPARα. Mol Endocrinol 16:1029-1039
10. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T 2003 Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκ B-C/EBP-β complex formation. Blood 101:545-551
11. Straus DS, Glass CK 2007 Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28:551-558
12. Pascual G, Glass CK 2006 Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab 17:321-327
13. Ricote M, Glass CK 2007 PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 1771:926-935
14. Ghisletti S, Huang W, Ogawa S, Pascual G, Lin ME, Willson TM, Rosenfeld MG, Glass CK 2007 Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARγ. Mol Cell 25:57-70
15. Levine B, Kalman J, Mayer L, Fillit HM, Packer M 1990 Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236-241
16. Oral H, Kapadia S, Nakano M, Torre-Amione G, Lee J, Lee-Jackson D, Young JB, Mann DL 1995 Tumor necrosis factor-α and the failing human heart. Clin Cardiol 18:IV20-IV27
17. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL 1996 Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27:1201-1206
18. Takeishi Y, Kubota I 2009 Role of Toll-like receptor mediated signaling pathway in ischemic heart. Front Biosci 14:2553-2558
19. Ozsoy HZ, Sivasubramanian N, Wieder ED, Pedersen S, Mann DL 2008 Oxidative stress promotes ligand-independent and enhanced ligand-dependent tumor necrosis factor receptor signaling. J Biol Chem 283:23419-23428
20. Zhang M, Chen L 2008 Status of cytokines in ischemia reperfusion induced heart injury. Cardiovasc Hematol Disord Drug Targets 8:161-172
21. Li X, Moody MR, Engel D, Walker S, Clubb Jr FJ, Sivasubramanian N, Mann DL, Reid MB 2000 Cardiac-specific overexpression of tumor necrosis factor-α causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation 102:1690-1696
22. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, Saito T, Masuda Y 2000 Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-α expression in neonatal rat cardiac myocytes. Circ Res 87:596-602
23. Ye P, Fang H, Zhou X, He YL, Liu YX 2004 Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-α expression in neonatal rat cardiac myocytes. Chin Med Sci J 19:243-247
24. Ding G, Cheng L, Qin Q, Frontin S, Yang Q 2006 PPARδ modulates lipopolysaccharide-induced TNFα inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 40:821-828
25. Abe J 2007 Role of PKCs and NF-κB activation in myocardial inflammation: enemy or ally? J Mol Cell Cardiol 43:404-408
26. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL 2004 PPAR α activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 36:295-304
27. Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G, Yamada A, Kato T, Izawa H, Murohara T, Yokota M 2006 Attenuation of cardiac dysfunction by a PPAR-α agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol 41:318-329
28. Young ME, Laws FA, Goodwin GW, Taegtmeyer H 2001 Reactivation of peroxisome proliferator-activated receptor α is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 276:44390-44395
29. Smeets PJ, Teunissen BE, Planavila A, de Vogel-van den Bosch H, Willemsen PH, van der Vusse GJ, van Bilsen M 2008 Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARα and PPARδ. J Biol Chem 283:29109-29118
30. Smeets PJ, Teunissen BE, Willemsen PH, van Nieuwenhoven FA, Brouns AE, Janssen BJ, Cleutjens JP, Staels B, van der Vusse GJ, van Bilsen M 2008 Cardiac hypertrophy is enhanced in PPARα -/- mice in response to chronic pressure overload. Cardiovasc Res 78:79-89
31. Smeets PJ, de Vogel-van den Bosch HM, Willemsen PH, Stassen AP, Ayoubi T, van der Vusse GJ, van Bilsen M 2008 Transcriptomic analysis of PPARα-dependent alterations during cardiac hypertrophy. Physiol Genomics 36:15-23
32. Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN, Schiffrin EL 2003 Peroxisome proliferator-activated receptor-α and receptor-γ activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 42:737-743
33. Guellich A, Damy T, Lecarpentier Y, Conti M, Claes V, Samuel JL, Quillard J, Hébert JL, Pineau T, Coirault C 2007 Role of oxidative stress in cardiac dysfunction of PPARα -/- mice. Am J Physiol Heart Circ Physiol 293:H93-H102
34. Liang F, Wang F, Zhang S, Gardner DG 2003 Peroxisome proliferator activated receptor (PPAR)α agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology 144:4187-4194
35. Li R, Zheng W, Pi R, Gao J, Zhang H, Wang P, Le K, Liu P 2007 Activation of peroxisome proliferator-activated receptor-α prevents glycogen synthase 3β phosphorylation and inhibits cardiac hypertrophy. FEBS Lett 581:3311-3316
36. Frey N, Olson EN 2003 Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65:45-79
37. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN 1998 A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215-228
38. Li CB, Li XX, Chen YG, Zhang C, Zhang MX, Zhao XQ, Hao MX, Hou XY, Gong ML, Zhao YX, Bu PL, Zhang Y 27 August 2008 Effects and mechanisms of PPARα activator fenofibrate on myocardial remodeling in hypertension. J Cell Mol Med
39. Fernandes-Santos C, Carneiro RE, de Souza Mendonca L, Aguila MB, Mandarim-de-Lacerda CA 2009 Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet. Nutrition 25:818-827
40. Lebrasseur NK, Duhaney TA, De Silva DS, Cui L, Ip PC, Joseph L, Sam F 2007 Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension. Hypertension 50:489-496
41. Rose M, Balakumar P, Singh M 2007 Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. Pharmacology 80:177-184
42. Duhaney TA, Cui L, Rude MK, Lebrasseur NK, Ngoy S, De Silva DS, Siwik DA, Liao R, Sam F 2007 Peroxisome proliferator-activated receptor α-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension 49:1084-1094
43. Nissen SE, Wolski K, Topol EJ 2005 Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294:2581-2586
44. Cheng AY, Fantus IG 2004 Thiazolidinedione-induced congestive heart failure. Ann Pharmacother 38:817-820
45. Lipscombe J, Lewis GF, Cattran D, Bargman JM 2001 Deterioration in renal function associated with fibrate therapy. Clin Nephrol 55:39-44
46. Seber S, Ucak S, Basat O, Altuntas Y 2006 The effect of dual PPAR α/γ stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract 71:52-58
47. Kasuga J, Makishima M, Hashimoto Y, Miyachi H 2006 Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor α/δ dual agonists. Bioorg Med Chem Lett 16:554-558
48. Xu Y, Etgen GJ, Broderick CL, Canada E, Gonzalez I, Lamar J, Montrose-Rafizadeh C, Oldham BA, Osborne JJ, Xie C, Shi Q, Winneroski LL, York J, Yumibe N, Zink R, Mantlo N 2006 Design and synthesis of dual peroxisome proliferator-activated receptors γ and δ agonists as novel euglycemic agents with a reduced weight gain profile. J Med Chem 49:5649-5652
49. Kasuga J, Yamasaki D, Araya Y, Nakagawa A, Makishima M, Doi T, Hashimoto Y, Miyachi H 2006 Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) α/δ dual agonists for the treatment of metabolic syndrome. Bioorg Med Chem 14:8405-8414
50. Pourcet B, Fruchart JC, Staels B, Glineur C 2006 Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs 11:379-401
51. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M 2007 PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res 56:91-98
52. Zhu W, Hassink RJ, Rubart M, Field LJ 2009 Cell-cycle-based strategies to drive myocardial repair. Pediatr Cardiol 30:710-715
53. Couffinhal T, Dufourcq P, Barandon L, Leroux L, Duplaa C 2009 Mouse models to study angiogenesis in the context of cardiovascular diseases. Front Biosci 14:3310-3325
54. Dzau VJ, Braun-Dullaeus RC, Sedding DG 2002 Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 8:1249-1256
55. Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, Sevestre H, Krimpenfort P, Corsini A, Rochette J, Glineur C, Fruchart JC, Torpier G, Staels B 2005 PPAR α inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest 115:3228-3238
56. Lefebvre P, Chinetti G, Fruchart JC, Staels B 2006 Sorting out the roles of PPAR α in energy metabolism and vascular homeostasis. J Clin Invest 116:571-580
57. Grau R, Díaz-Muñoz MD, Cacheiro-Llaguno C, Fresno M, Iñiguez MA 2008 Role of peroxisome proliferator-activated receptor α in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth. PPAR Res 2008:352437
58. Folkman J 1995 Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31
59. Carmeliet P, Jain RK 2000 Angiogenesis in cancer and other diseases. Nature 407:249-257
60. Bergers G, Benjamin LE 2003 Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410
61. Ferrara N 2000 VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 11:617-624
62. Cross MJ, Claesson-Welsh L 2001 FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22:201-207
63. Shibuya M, Claesson-Welsh L 2006 Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312:549-560
64. Shibuya M, Ito N, Claesson-Welsh L 1999 Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr Top Microbiol Immunol 237:59-83
65. Harper J, Moses MA 2006 Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS:223-268
66. Griffioen AW, Molema G 2000 Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52:237-268
67. Meissner M, Stein M, Urbich C, Reisinger K, Suske G, Staels B, Kaufmann R, Gille J 2004 PPARα activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res 94:324-332
68. Grau R, Punzón C, Fresno M, Iñiguez MA 2006 Peroxisome-proliferator-activated receptor α agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Biochem J 395:81-88
69. Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnés CM, Fannon M, Laforme AM, Chaponis DM, Folkman J, Kieran MW 2008 PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 105:985-990
70. Shigeto T, Yokoyama Y, Xin B, Mizunuma H 2007 Peroxisome proliferator-activated receptor α and γ ligands inhibit the growth of human ovarian cancer. Oncol Rep 18:833-840
71. Yokoyama Y, Xin B, Shigeto T, Umemoto M, Kasai-Sakamoto A, Futagami M, Tsuchida S, Al-Mulla F, Mizunuma H 2007 Clofibric acid, a peroxisome proliferator-activated receptor α ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther 6:1379-1386
72. Blann AD, Belgore FM, Constans J, Conri C, Lip GY 2001 Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 87:1160-1163
73. Neubauer S 2007 The failing heart - an engine out of fuel. N Engl J Med 356:1140-1151
74. Mukherjee R, Jow L, Noonan D, McDonnell DP 1994 Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol 51:157-166
75. Braissant O, Foufelle F, Scotto C, Dauçca M, Wahli W 1996 Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137:354-366
76. Harris GS, Lust RM, DeAntonio JH, Katwa LC 2008 PPAR-γ expression in animals subjected to volume overload and chronic Urotensin II administration. Peptides 29:795-800
77. Qin HD, Huang D, Weng XD, Xu F 2009 Upregulation of peroxisome proliferator-activated receptor-γ and NADPH oxidases are involved in restenosis after balloon injury. J Cell Physiol 221:387-393
78. Stanley WC, Recchia FA, Lopaschuk GD 2005 Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85:1093-1129
79. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W1996 The PPAR alpha-leukotriene B4 pathway to inflammation control. Nature 384:39-43
80. Takano H, Hasegawa H, Nagai T, Komuro I 2003 The role of PPARγ dependent pathway in the development of cardiac hypertrophy. Drugs Today (Barc) 39:347-357